Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD)

Hematology

Volumn 15, Issue 2, 2010, Pages 70-73

  Wang, M ^a   Delasalle, K ^a   Giralt, S ^a   Alexanian, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Autologous stem cell transplantation; Bortezomib; Dexamethasone; Lenalidomide; Multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VALACICLOVIR; WARFARIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER REGRESSION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRY SKIN; EDEMA; EVENING DOSAGE; FATIGUE; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; INSOMNIA; IRRITABILITY; MALE; MULTIPLE MYELOMA; NEUROPATHY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG EVALUATION; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NERVOUS SYSTEM DISEASES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PYRAZINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; THALIDOMIDE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 77952170192     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12583347010133     Document Type: Article

References (24)

1. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
2. Richardson P, Mitsiades C, Schlossman R et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 1053-1072.
3. Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995.
4. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
5. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
6. Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235-239.
7. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
8. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
9. Rajkumar SV, Hayman S, LacyMet al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
10. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
11. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
12. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-491.
13. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
14. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
15. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
16. Singhal S, Powles R, Sirohi B et al. Response to induction chemotherapy is not essential to obtain survival benefit from highdose melphalan and auto transplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679.
17. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229-234.
18. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Eng J Med 2007; 357: 2133-2142.
19. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
20. Rajkumar S, Jacobus S, Callander R et al. Lenalidomide plus highdose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma. Lancet Oncol 2010; 11: 29-37.
21. Popat R, Oakervee H, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma. Br J Haematol 2008; 141: 512-516.
22. Jagannath S, Durie B, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783.
23. Lahuerta J, Mateos M, Martinez J et al. Influence of pre-and posttransplantation responses on outcome of patients with multiple myeloma. J Clin Oncol 2008; 26: 5775-5782.
24. Barlogie B, Tricot G, van Rhee F et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.